Jeannie David has been with the Drug Shortage Staff since 2012 and has worked on several drug shortage mitigation efforts, as well as on the Guidance to Industry Notifying FDA of a Permanent Discontinuance or Interruption in Manufacturing, MAPP 5001.1 Drug Product Distribution After a Complete Response Action, and the FDA Drug Shortage Strategic Plan. Jeannie David also participates in multiple FDA working groups, such as the Office of Pharmaceutical Quality's pilot Site Engagement Program to improve quality manufacturing. She joined FDA in 2008 as a project manager for pharmaceutical quality review of new drug applications. Prior to joining FDA, Jeannie was in early stage target identification and drug development in academia and industry.